Skip to main content
OpenTrials
Completed

NCT Number: NCT06207435

Community Support Program for Lung Cancer Screening

The research study aims to create a program for lung cancer screening attendance

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Lung Cancer Behavior Lung Diseases Lung Neoplasms Neoplasms Neoplasms by Site Respiratory Tract Diseases Respiratory Tract Neoplasms Thoracic Neoplasms

Age range

18 year–89 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

About this study

The overall objective of this project is to demonstrate the impact of a community support program (CSP) on improving adherence to LCS follow-up guidelines in an urban environment. The project aims to collaborate with community partners to develop an infrastructure and iterative process to provide social support to community members that facilitates obtaining their follow-up LDCT for LCS. It utilizes novel population level data that includes geospatial analysis of neighborhood-level data of patients residing in Philadelphia who have received a LDCT for LCS. This allows for targeted community level interventions and the ability to evaluate impact on a population level.

A Community Support Program Representative will reach out to eligible patients via telephone. The CSP Representative and Patient Navigator will communicate with consented patient directly, assist with travel and the appointment. The PN will log the date of the appointment, zip code of the patient and the adherence (or lack of) of the appointment completion. We will utilize Lyft transportation vouchers to provide rides to participants from their home location in West Philadelphia to and from the Penn Medicine downtown hospital locations on the day of their LDCT.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Upcoming or missed follow-up LDCT (low dose CT)
  • West Philadelphia resident
  • Between 18-89 years' old

Exclusion criteria

  • No upcoming LDCT
  • Lives outside West Philadelphia
  • Outside age range

Treatment and study plan

Transportation

Behavioral

Eligible patients are contacted and offered free transportation to and from their upcoming appointment.

Primary outcomes

  1. Percentage of Scheduled Lung Cancer Screening Appointments Attended by Participants

    Time frame: 12 months

    The Primary Outcome measures the rate of appointment attendance across three groups: West Philadelphia CSP Participants (eligible West Philadelphia residents who opted into the CSP), West Philadelphia Non CSP Participants (eligible West Philadelphia residents who did not opt into the CSP), and Southwest Philadelphia Residents (patients who did not receive an option to participate in the CSP).

Secondary outcomes

  1. Percentage of CSP Enrollment

    Time frame: 12 months

    The Secondary outcome is a measurement of the percentage of eligible participants (West Philadelphia residents) who chose to opt into the CSP (as opposed to eligible participants who did not).

Sponsors and collaborators

Lead sponsor

Abramson Cancer Center at Penn Medicine

Other

Registry information

Acronym: LCS

Important dates

Study start
2023
Primary completion
2024
Study completion
2024
First posted
Jan 17, 2024
Registry last updated
Sep 2, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.